Cann Group (ASX:CAN) - CEO, Peter Crock
CEO, Peter Crock
Source: Cannabis Club Australia
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Medical cannabis company Cann Group (CAN) has announced that investor Aurora Cannabis has dropped its stake in the company
  • Aurora sold its 11.84 per cent shareholding in Cann via off-market trades to a small number of buyers
  • Aurora said its plan to sell is consistent with its current strategic priorities
  • Nevertheless, Cann has reassured shareholders that Aurora’s decision will not impact its business plans
  • On the market today, Cann is down 7.14 per cent, trading for 39 cents per share

Medical cannabis company Cann Group (CAN) has announced that investor Aurora Cannabis has dropped its stake in the company.

On Friday, Aurora sold its 11.84 per cent shareholding in Cann via off-market trades to a small number of buyers.

Aurora said its plan to sell is consistent with its current strategic priorities.

Nevertheless, Cann has reassured shareholders that Aurora’s decision will not impact its business plans.

Currently, the company is “developing a growing and diversified supply base with business to business (B2B) customers in Australia and overseas and proceeding with plans to expand its manufacturing capacity.”

In August, the company’s 2020 financial year results came out. Cann’s full-year revenue slipped 56 per cent to $1.86 million compared to the previous financial year.

With the Mildura facility expansion, Cann is expecting around $15 million in revenue for the 2021 financial year.

On the market today, Cann is down 7.14 per cent, trading for 39 cents per share at 12:31pm AEDT.

can by the numbers
More From The Market Online

BlinkLab forms partnership with US autism foundation

BlinkLab’s collaboration the SHANK2 foundation will provide it with access to genetically confirmed patient populations.
CT scan of lungs

The ides of March come for Immutep as lung cancer trial cancellation triggers plummet

Immutep Ltd (ASX:IMM) has seen its share price slaughtered on Friday after it’s effectively ditched its lead candidate for

Patrys begins key activities for delirium candidate

Patrys has commenced key manufacturing and regulatory activities for a candidate being developed to alleviate delirium.

EVE Health Group to target global markets with reformulated drugs

EVE Health Group will test global markets after successfully completing R&D work on several reformulated drug…